INVO Fertility Inc

IVF

Market cap $12.9M

SARASOTA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit, taking place virtually on Thursday, January 15, 2026.

SARASOTA, Fla. and INDIANAPOLIS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has signed a definitive purchase agreement to acquire Family Beginnings, P.C.

SARASOTA, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 2,366,864 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,733,728 shares of common stock, in a private placement priced at-the-market under Nasdaq rules (the “Offering”). The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying warrants is $1.69. The warrants will have an exercise price of $1.69 per share, will be exercisable upon shareholder approval and will expire on the five year anniversary from such date of shareholder approval.

Acquisition advances INVO's national expansion strategy, enhances its clinical capabilities, and broadens access to innovative fertility care across the Midwest Acquisition advances INVO's national expansion strategy, enhances its clinical capabilities, and broadens access to innovative fertility care across the Midwest

SARASOTA, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-8 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on November 28, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on November 28, 2025, the Company's common stock will trade on a post-split basis under the same trading symbol, “IVF”.

SARASOTA, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced third quarter 2025 financial results.

MIDDLETON, Wis. and SARASOTA, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced a strategic partnership with Heidi Health to integrate its innovative AI-powered scribe platform at INVO's Wisconsin Fertility Institute (WFI).

SARASOTA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced second quarter 2025 financial results.

SARASOTA, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-3 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on July 21, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on July 21, 2025, the Company's common stock will trade on a post-split basis under the same trading symbol, “IVF”.